Expand all sections

Fezolinetant

unknown

Extended indication

Veoza is indicated for the treatment of moderate to severe vasomotor symptoms (VMS) associated with

Therapeutic value

No estimate possible yet
Registration phase

Positive CHMP opinion

Product

Active substance

Fezolinetant
Domain

Metabolism and Endocrinology
Reason of inclusion

New medicine (specialité)
Main indication

Metabolic diseases
Extended indication

Veoza is indicated for the treatment of moderate to severe vasomotor symptoms (VMS) associated with menopause.
Proprietary name

unknown
Manufacturer

Astellas
Portfolio holder

Astellas
Mechanism of action

Receptor antagonist
Route of administration

Oral
Therapeutical formulation

Tablet
Budgetting framework

Extramural (GVS)
Additional remarks 
Neurokinine-3-receptor antagonist

Registration

Registration route

Centralised (EMA)
ATMP

No
Submission date

August 2022
Expected Registration

December 2023
Orphan drug

No
Registration phase

Positive CHMP opinion
Additional remarks 
Positieve CHMP-opinie oktober 2023

Therapeutic value

Current treatment options

De standaard geneesmiddelbehandeling voor vasomotorische symptomen in de menopauze is hormoontherapie met een combinatie van oestrogeen en progesteron, of oestrogeen alleen.
Therapeutic value

No estimate possible yet
Frequency of administration

1 times a day

Expected patient volume per year

There is currently nothing known about the expected patient volume.

Expected cost per patient per year

Additional remarks 
De lijstprijs zal eind 2023 bekend zijn.

Potential total cost per year

There is currently nothing known about the possible total cost.

Off label use

There is currently nothing known about off label use.

Indication extension

Indication extension

No
References 
adisinsght

Other information

There is currently no futher information available.